Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment

This study has been completed.
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01031875
First received: December 13, 2009
Last updated: August 9, 2013
Last verified: September 2012